References
- Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807–810.
- McWilliams RR, Rao RD, Buckner JC, et al. Melanoma-induced brain metastases. Expert Rev Anticancer Ther. 2008;8:743–755.
- Hong A, Fogarty G, Izard MA. The role of radiation therapy in the management of metastatic melanoma in the brain. Int J Surg Oncol. 2012;2012:294735.
- Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293–1300.
- Samlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855–1862.
- Stone A, Cooper J, Koenig KL, et al. A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest. 2004;22:492–497.
- Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1839–1842.
- Bentzen SM, Overgaard J, Thames HD, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol. 1989;16:169–182.
- Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1971;44:816–817.
- Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol Oncol. 1986;25:1–10.
- Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 1991;20:429–432.
- Khan N, Khan MK, Almasan A, et al. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80:645–654.
- Sambade MJ, Peters EC, Thomas NE, et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98:394–399.
- Joiner M, Bentzen SM, Basic clinical radiobiology: Fractionation: The linear quadratic approach. 4th ed. London: Hodder Arnold; 2009.
- Nilsson P, Thames HD, Joiner MC. A generalized formulation of the 'incomplete-repair' model for cell survival and tissue response to fractionated low dose-rate irradiation. Int J Radiat Biol. 1990;57:127–142.
- Nyman J, Turesson I. Does the interval between fractions matter in the range of 4-8 h in radiotherapy? A study of acute and late human skin reactions. Radiother Oncol. 1995;34:171–178.
- Rades D, Heisterkamp C, Huttenlocher S, et al. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys. 2010;77:537–541.
- Choi KN, Withers HR, Rotman M. Metastatic melanoma in brain. Rapid treatment or large dose fractions. Cancer. 1985;56:10–15.
- Meier S, Baumert BG, Maier T, et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie. 2004;27:145–149.
- Sampson JH, Carter JH, Jr., Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11–20.
- Morris SL, Low SH, A'hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91:829–833.
- Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76:S20–S27.
- Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002;38:487–496.